Avecho Biotechnology Income Statement

Financials in millions AUD. Fiscal year is January - December.

Millions AUD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1.24	1.13	0.47	1.13	0.79
Revenue Growth (YoY)	9.28%	139.19%	-58.06%	42.30%	106.33%
Cost of Revenue	0.35	0.46	0.52	0.34	0.29
Gross Profit	0.89	0.67	-0.04	0.79	0.51
Selling, General & Admin	2.58	2.04	2.43	2.26	2.92
Research & Development	2.26	1.7	0.95	0.87	0.99
Operating Expenses	4.84	3.74	3.38	3.13	3.91
Operating Income	-3.96	-3.06	-3.42	-2.34	-3.41
Interest Expense	-0.46	-0.06	-0.02	-0.01	-0.01
EBT Excluding Unusual Items	-4.42	-3.12	-3.44	-2.34	-3.42
Pretax Income	-4.42	-3.12	-3.44	-2.34	-3.42
Earnings From Continuing Operations	-4.42	-3.12	-3.44	-2.34	-3.42
Net Income	-4.42	-3.12	-3.44	-2.34	-3.42
Net Income to Common	-4.42	-3.12	-3.44	-2.34	-3.42
Shares Outstanding (Basic)	3,267	3,169	2,268	1,838	1,802
Shares Outstanding (Diluted)	3,267	3,169	2,268	1,838	1,802
Shares Change (YoY)	3.08%	39.73%	23.41%	1.97%	13.27%
EPS (Basic)	-0.00	-0.00	-0.00	-0.00	-0.00
EPS (Diluted)	-0.00	-0.00	-0.00	-0.00	-0.00
Free Cash Flow	1.1	-3.97	-3.18	-1.72	-3.3
Free Cash Flow Per Share	-	-0.00	-0.00	-0.00	-0.00
Gross Margin	71.77%	59.32%	-9.25%	70.23%	64.00%
Operating Margin	-319.55%	-270.59%	-722.46%	-206.86%	-429.20%
Profit Margin	-356.82%	-275.64%	-725.70%	-207.43%	-430.46%
Free Cash Flow Margin	89.12%	-350.38%	-671.51%	-152.16%	-416.01%
EBITDA	-3.82	-2.92	-3.24	-2.11	-2.98
EBITDA Margin	-	-257.80%	-	-186.47%	-
D&A For EBITDA	0.14	0.14	0.18	0.23	0.43
EBIT	-3.96	-3.06	-3.42	-2.34	-3.41
EBIT Margin	-	-270.59%	-	-206.86%	-

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.